The critical involvement of dopamine in cognitive processes has been well established, suggesting that therapies targeting dopamine metabolism may alleviate cognitive dysfunction. Catechol-O-methyl transferase (COMT) is a catecholamine-degrading enzyme, the substrates of which include dopamine, epinephrine, and norepinephrine. The present work illustrates the potential therapeutic efficacy of COMT inhibition in alleviating cognitive impairment. A brainpenetrant COMT inhibitor, tolcapone, was tested in normal and phencyclidine-treated rats and COMT-Val transgenic mice. In a novel object recognition procedure, tolcapone counteracted a 24-h-dependent forgetting of a familiar object as well as phencyclidine-induced recognition deficits in the rats at doses ranging from 7.5 to 30 mg/kg. In contrast, entacapone, a COMT inhibitor that does not readily cross the blood-brain barrier, failed to show efficacy at doses up to 30 mg/kg. Tolcapone at a dose of 30 mg/kg also improved novel object recognition performance in transgenic mice, which showed clear recognition deficits. Complementing earlier studies, our results indicate that central inhibition of COMT positively impacts recognition memory processes and might constitute an appealing treatment for cognitive dysfunction related to neuropsychiatric disorders. Behavioural Pharmacology 27:415-421
Introduction
The role of dopamine in cognitive processes, under normal or pathological conditions such as schizophrenia or Parkinson's disease, is well established (Dujardin and Laurent 2003; Brisch et al., 2014; Chandler et al., 2014) . Cognitive dysfunction is a key, yet clinically untreated, symptom of schizophrenia (Millan et al., 2010; Nuechterlein et al., 2014) , and dopaminergic drugs have been proposed to ameliorate cognitive impairment associated with schizophrenia (CIAS). Stimulating postsynaptic or perisynaptic dopaminergic receptors such as D1/5, or increasing dopamine in the synaptic cleft by inhibiting a key catabolic pathway for cortical dopaminethat is, catechol-O-methyl transferase (COMT)may be a viable strategy for ameliorating cognitive deficits related to the frontotemporal dysfunction observed in this disorder. However, brain-penetrant D1/5 agonists and COMT inhibitors (e.g. tolcapone) advanced to human clinical trials have important side effects, such as hypotension for D1/5 agonists and idiosyncratic hepatotoxicity for tolcapone. Nevertheless, they can be used as tools for short-term proof of concept in animals and humans.
Tolcapone has been studied in normal volunteers stratified by the functional Val158Met polymorphism on COMT and, as predicted, tolcapone has been shown to ameliorate working memory and executive dysfunctions in individuals having increased DA metabolism (Val-Val genotypes), compared with those bearing the Met-Met allele Farrell et al., 2012) . Preclinical research with COMT-Val transgenic mice has shown that they have increased COMT activity compared with control littermates and significant deficits in novel object recognition (NOR). The NOR deficit could be reversed with acute amphetamine treatment immediately after the acquisition trial (Papaleo et al., 2008) . These data indicate that manipulation of the dopaminergic system is a viable strategy for modulating cognitive function in COMT-Val transgenic mice, and the current paper assessed tolcapone efficacy in this paradigm.
There is a paucity of preclinical, in particular rodent, studies using tolcapone as a pharmacological probe to evaluate the impact of increased DA function on different cognitive domains both in normal and pathological animals.
Apart from the study by Khromova et al. (1997) that demonstrated dose-dependent efficacy of tolcapone (1, 3, 10 mg/kg, intraperitoneally), with the highest dose clearly reversing scopolamine-induced deficits in an inhibitory avoidance procedure, all the subsequently published studies utilizing tolcapone in cognitive tasks used a single dose. For example, tolcapone tested at a dose of 3 mg/kg (intraperitoneally) has been shown to slightly improve the number of correct choices in aged rats that were selected as poor performers when trained in a working memory protocol using a linear maze (Liljequist et al., 1997) . Tunbridge et al. (2004) tested tolcapone in rats at a dose of 30 mg/kg (intraperitoneally) and indicated a beneficial effect of the compound in a set-shifting protocol. Specifically, tolcapone-treated rats reached criterion faster when they had to perform an extradimensional shift. Laatikainen et al. (2012) showed that, in a working memory procedure, a single dose of 30 mg/kg (intraperitoneally) improved delayed alternation performance of rats at short but not long delays. The authors also mentioned a positive impact of the same tolcapone dose in rats submitted to a novelty-preference procedure in a Y-maze task. Finally, in a delayed spatial win-shift procedure, 30 mg/kg tolcapone has been shown to improve performances of rats at an extended delay of 1 h but not at a 1-min delay (Lapish et al., 2009) . To our knowledge, the only published study, other than the one by Khromova et al. (1997) , in which several doses of tolcapone have been used (3-30 mg/kg) reported that it was ineffective in rats performing at a suboptimal level (reduced accuracy) in a five-choice serial reaction time task (Paterson et al., 2011) .
Until now, there is no published study evaluating the impact of tolcapone on the NOR paradigm or on animal models relevant for CIAS such as chronic, low-dose phencyclidine (PCP)-treated rats (for review see Morris et al., 2005; Pratt et al., 2008) . Interestingly, some dopaminergic D1 agonists showed efficacy in this model when animals were evaluated in a NOR procedure (McLean et al., 2009; Horiguchi et al., 2013) .
The objective of the present study was two-fold. The first aim was to evaluate the impact of tolcapone in a NOR protocol using normal and PCP-treated rats. A range of doses covering different levels of enzyme inhibition were investigated in 24-h delay-dependent forgetting of a familiar object in rats. Entacapone, a noncentral nervous system penetrant COMT inhibitor, was also tested in this procedure as a negative control. We then evaluated the impact of the effective doses of tolcapone in rats treated with subchronic PCP (twice daily for 7 days, followed by a 7-day washout period), a procedure used to model cognitive deficits analogous to schizophrenia. NOR has been proposed as a valuable paradigm for CIAS (see Lyon et al., 2012 for a review), particularly in rats, following subchronic treatment with PCP (Redrobe et al., 2010) . The second aim was to evaluate the efficacy of tolcapone in COMT-Val transgenic mice, which also show endogenous deficits in the NOR task.
The present results indicate that tolcapone is able to counteract recognition memory deficits observed in normal rats submitted to a 24-h delay procedure, in subchronic PCP-treated rats submitted to a 30-min delay procedure, and in COMT-Val transgenic mice submitted to a 1-h delay procedure.
Methods

Subjects Rats
Sprague-Dawley and Long-Evans rats (2-3 months old) were used; the second strain was selected for its high susceptibility to PCP treatment. The rats were group-housed, with free access to food and water, in a temperature and humidity controlled animal facility (12 : 12 h light : dark cycle). The individual rat strain used depended on the model and the cognitive task, as detailed below. Behavioral experiments were carried out between 09:00 and 14:00 h in a sound-attenuated and air-regulated experimental room. All animal procedures were conducted in strict adherence to the European Union Directive 2010/63/EU and were approved by UCB Ethics Committee
COMT-Val transgenic mice
The origin of the COMT-Val transgenic mice used in these experiments has been previously described in detail (Papaleo et al., 2008) . Briefly, COMT-Val transgenic mice express the human Val form of the COMT gene, under the control of the NSE-tTA promoter, along with normal expression of wild-type mouse COMT. The COMT-Val mice exhibit roughly 20% more endogenous COMT enzyme activity in the cortex compared with their littermate controls. Genotypes were identified by PCR analysis of tail DNA. The mice were group-housed (two to four mice per cage) in a climate-controlled animal facility and maintained on a 12 h light/dark cycle (lights on at 06:00 h) with free access to food and water. All testing was performed on 12-24-week-old male mice during the light phase. All procedures were approved by the National Institute of Mental Health Animal Care and Use Committee and followed the Guide for the Care and Use of Laboratory Animals.
Novel object recognition task in rats
The experimental arena was a square box (60 × 60 × 40 cm). The arena and the objects were cleaned between each trial to avoid odor trails left by the rats. The arena was placed in a dark room illuminated only by halogen lamps oriented toward the ceiling and giving a uniform, dim light in the box (around 60 lux). The animals to be tested were placed in the experimental room at least 30 min before testing. The day before the test, the rats were allowed to freely explore the box for 6 min (habituation trial).
Rats were subjected two object exploration trials (acquisition and retention) spaced by an intertrial interval, the duration of which is specified in Table 1 . During the first trial (acquisition trial), rats explored two copies of an object (familiar object); the time required to complete a fixed duration of object exploration was determined, with a maximal cutoff time of 4 min. Exploration was considered to include directing the nose at a distance less than 2 cm from the object and/or touching the object. Experimenters were unaware of drug treatments to ensure blinding and avoid bias. During the retention trial, one of the two familiar objects was replaced by an unknown object (novel object), and the time spent exploring each object was recorded over 4 min. The animals with naturally low levels of spontaneous exploration (total exploration lower than 6 s) were excluded. About 10-15% of rats showed a low level of exploration. A recognition index was calculated by subtracting the amount of time spent exploring the familiar object from the amount of time spent exploring the novel object, divided by the total exploration time.
Novel object recognition task in transgenic mice
The NOR protocol utilized in these experiments was similar to that used previously in COMT-Val transgenic mice (Papaleo et al., 2008) . Testing was conducted in a clear, acrylic open-field arena (42 × 42 × 30 cm). On day 1 of testing, the mice were allowed to freely explore the empty arena for 60 min. On day 2, the mice were placed back into the open field for a 10-min period (acquisition phase), during which they were allowed to explore two identical copies of an object. The objects were either rectangular boxes (4 × 4 × 7 cm) or Erlenmeyer flasks (4 × 7 cm). Both types of objects could be either white or black. Immediately after the acquisition phase, the mice were given an injection of vehicle or tolcapone (30 mg/kg, intraperitoneally). One hour later, the mice were placed back into the open field (retention phase) with a copy of the object encountered previously and a novel object, which differed from the familiar object in both color and shape. The testing sessions were videotaped and later scored by an observer blind to genotype. The time spent exploring each object was recorded, and a recognition index to determine recognition memory was obtained by subtracting the amount of time spent exploring the familiar object from the amount of time spent exploring the novel object, divided by the total exploration time.
Statistical analysis
The NOR test was analyzed using a two-way mixed analysis of variance (ANOVA), with Holm-Sidak posthoc testing to compare the time spent exploring the novel object versus the familiar object. The factors for the ANOVA were drug treatment and prior experience with the object (familiar or novel). The index was analyzed either by one-way ANOVA followed by least significant difference post-hoc analysis (rats) or using a ttest for comparison of COMT-Val transgenic mice and their littermate controls. Significance was set at P-values less than 0.05. All graphs represent data as mean SEM.
Drugs
Tolcapone (synthetized by Apichem Technology, Hangzhou, Zhejiang, China) was delivered to rats through the intraperitoneal route as a suspension in 0.1% Tween80 with 0.1% 1510 silicone antifoam in 1% methylcellulose to final concentration. For the COMT-Val transgenic mouse experiment, tolcapone was purchased from AK Scientific Inc. (Union City, California, USA), suspended in a vehicle of 20% (2-hydroxypropyl)-β-cyclodextrin in saline, and administered intraperitoneally at a dose of 30 mg/kg. The injection volumes were 5 and 10 ml/kg for rats and mice, respectively.
Results
Tolcapone improved delay-dependent forgetting of novel object recognition in rats Twenty-four hours after presentation of a familiar object, the rats receiving vehicle showed similar exploration of familiar and novel objects. Tolcapone administered 40 min before acquisition increased the time spent exploring the novel object compared with the familiar object during the retention trial [interaction effect: F(5,60) = 4.27, P < 0.005]. Post-hoc analysis showed that the 15 mg/kg group was significantly different from the vehicle-treated group (P < 0.002; Fig. 1a ). The 7.5 mg/kg and 30 mg/kg groups had effects that did not survive correction for multiple comparisons. This increase translated into a dose-dependent increase in the recognition index from 7.5 to 30 mg/kg. Vehicle-treated rats showed a recognition index close to 0, indicating their inability to discriminate between the two objects when delay between the acquisition trial (exploration of familiar object) and the retention trial (discrimination between the familiar object and a novel one) was 24 h (Fig. 1b) . Tolcapone improved discrimination between the two objects as the recognition index increased from 3.3 4.3% in vehicle-treated rats to 33.6 6.6% at 15 mg/kg. This increase was statistically significant at doses ranging from 7.5 to 30 mg/kg [F(5,65) = 5.10, P = 0.001]. Tolcapone did not impact total object exploration [F(5,65) = 1.00, NS] (data not shown). The efficacy of entacapone was assessed at doses ranging from 7.5 to 30 mg/kg (Fig. 2) . Exploration of the novel object during the retention trial was similar to exploration of the familiar object at all doses of entacapone. There was a significant interaction effect [F(4,58) = 4.67, P < 0.005], driven by significant effects of the tolcapone-positive control group (P < 0.005). The recognition indices of mice treated with entacapone (7.5, 15, and 30 mg/kg) were not statistically different from those of vehicle-treated rats (P = 0.65, 0.65, and 0.054 for 7.5, 15, 30 mg/kg, respectively). It is to be noted that the highest (30 mg/kg) entacapone dose showed a trend toward improvement, but it did not reach statistical significance. The 7.5 mg/kg tolcapone dose was included as a positive control in this experiment. Tolcapone significantly increased the recognition index (P < 0.01). The total exploration time was unaffected by treatment [F(5,63) = 0.52, NS].
Tolcapone ameliorated subchronic phencyclidineinduced novel object recognition deficit in rats
The efficacy of tolcapone was assessed at active doses in delay-dependent forgetting in an object recognition task following a subchronic PCP challenge, using a short (30 min) delay between acquisition and retention. Rats received subchronic PCP (5 mg/kg, twice daily for 7 days) or vehicle, followed by a 7-day washout period before the NOR task. Tolcapone or vehicle were administered 40 min before acquisition. Under this condition, vehicle control rats receiving vehicle for 7 days and vehicle before acquisition were able to discriminate novel from familiar objects during the retention trial. They spent more time exploring the novel than the familiar object (P < 0.001). In contrast, subchronic PCPtreated rats receiving vehicle before acquisition spent equal amounts of time exploring both objects during the retention trial (P > 0.05; Fig. 3a ). Tolcapone treatment before the acquisition trial increased the time spent exploring the novel object [interaction effect: F(4,85) = 8.33, P < 0.001]. This increase translated into a statistically significant increase in the recognition index (P < 0.001) at all the tested doses. The index increased from 6.0 4.8 to 38.1 5.3% at the 7.5 mg/kg dose (Fig. 3b) . None of the treatments significantly impacted overall exploration [F(4,89) = 0.25, NS] (data not shown).
Tolcapone reversed novel object recognition deficits observed in catechol-O-methyltransferase-Val transgenic mice
To characterize the effects of COMT inhibition in a model characterized by high baseline COMT activity, we tested tolcapone in an NOR task in COMT-Val transgenic mice (Fig. 4) . We found that acute administration of a 30 mg/kg dose immediately following the acquisition phase (see Papaleo et al., 2008) produced a significant difference between novel and familiar object exploration [interaction effect: F(1,10) = 5.51, P < 0.05]. The withingroup differences in novel and familiar object exploration translated into a significant effect of tolcapone on the recognition index [t(10) = 2.46, P < 0.05]. There was no significant difference between vehicle-treated and tolcapone-treated mice in the total exploration time during the retention trial [t(10) = 1.28, NS; data not shown].
Discussion
The present results show for the first time that central inhibition of COMT by tolcapone, at different doses, is able to reverse recognition memory deficits in normal rats submitted to a 24-h delay, as well as in subchronic PCPtreated rats tested at a short delaythat is, 30 min. In addition, tolcapone at a dose of 30 mg/kg was also shown to reverse recognition deficits observed in COMT-Val transgenic mice, a transgenic line expressing the COMT-Val form of human COMT, which results, functionally, in a gain of function of the COMT enzyme (Papaleo et al., 2008). The necessity for a central effect of tolcapone was demonstrated by showing that the poorly penetrant COMT inhibitor, entacapone, was not effective in NOR with a 24-h delay up to a dose of 30 mg/kg, the maximal dose tested. Related to this, Napolitano et al. (2003) showed that both entacapone and tolcapone produce, at similar doses, a comparable degree of peripheral COMT inhibition (liver and duodenum). Therefore, the lack of activity of entacapone cannot be explained by a smaller inhibitory effect at the COMT enzyme but rather by its poor brain penetration. This lack of effect of entacapone is in line with published data by Liljequist et al. (1997) showing that tolcapone (10 mg/kg) but not entacapone (10 and 30 mg/kg) was effective in facilitating spatial working memory in normal rats.
It is worth noting here that the minimal dose found to be statistically effective in the NOR 24-h delay in normal ratsthat is, 7.5 mg/kgwas lower than the dose that is supposed to fully inhibit the COMT enzymethat is, 30 mg/kgas reported in the literature (Aquas et al., 1992; Tunbridge et al., 2004) . However, this dose was shown by Aquas et al. (1992) to increase homovanillic acid (HVA) and decrease 3,4-dihydroxyphenylacetic acid (DOPAC) output in the caudate of freely moving rats. Using in-vivo microdialysis, we have been able to confirm these results and have shown that doses of 3.7-30 mg/kg (intraperitoneally) were effective in altering extracellular levels of HVA and DOPAC in the prefrontal cortex of freely moving Sprague-Dawley rats (data not shown). Therefore full inhibition of the COMT enzyme is not a necessary prerequisite for obtaining efficacy in these tasks. Indeed, the lowest statistically significant effective dose in the NOR 24-h delay in normal rats was found to be fully effective in subchronic PCP-treated rats. These results support the notion that central COMT inhibition might be of interest for cognitive deficits related to schizophrenia. Recent published findings obtained in our laboratory further indicate that tolcapone might ameliorate executive dysfunction, modeled by a set-shifting procedure performed in subchronic PCP-treated rats (Troudet et al., 2014) .
In COMT-Val transgenic mice, a single dose of 30 mg/kg tolcapone was used and was found to be very effective in a NOR protocol similar to that used by Papaleo et al. (2008) to show the ability of amphetamine to partially reverse the NOR deficits observed in this linethat is, by administering the compound after the acquisition trial. Further studies are planned to evaluate a dose-response of tolcapone in this procedure, as well as in a procedure in which tolcapone is administered before acquisition, to dissect the effect of tolcapone on acquisition versus its effects on consolidation and retrieval. It should also be of interest to study the effect of tolcapone on consolidation and retrieval processes in NOR in rats pretreated with PCP or submitted to a delay-dependent forgetting procedure.
COMT inhibition has been proposed as a strategy to improve prefrontal cortex-dependent cognitive dysfunction (Gasparini et al., 1997; Apud and Weinberger, 2007; Scheggia et al., 2012) . However, recent preclinical studies by Laatikainen et al. (2012 Laatikainen et al. ( , 2013 have pointed out that COMT inhibition might also ameliorate hippocampusdependent cognitive processes. COMT inhibition is thought to be an important mechanism for the termination of dopamine signaling in the cortex, owing to the paucity of dopamine transporters in this brain region, and cortical dopaminergic activity is thought to underlie many aspects of cognition (Lewis et al., 2001; Clark and Noudoost, 2014) . There is a large body of preclinical research indicating that COMT inhibition improves cognitive function across multiple domains (Khromova et al., 1997; Tunbridge et al., 2004; Lapish et al., 2009; Laatikainen et al., 2012; Risbrough et al., 2014) ; therefore, it seems plausible that central COMT inhibition may impact different brain areas beyond the cortex or hippocampus. In addition, data from small clinical studies have suggested that tolcapone improves cognitive function in healthy individuals and in people with Parkinson's disease (Gasparini et al., 1997; . Although tolcapone is an effective, brain-penetrant COMT inhibitor, concerns about long-term safety have limited its widespread use in the clinic (Kaakkola., 2010) . The significant contribution of the mesocortical dopaminergic system to cognition and the experimental evidence of tolcapone improving cognitive function in a variety of tasks indicate the usefulness of an approach targeting the design of safe, noncatechol, brain-penetrant COMT inhibitors for the symptomatic treatment of cognitive disorders in aging and in neuropsychiatric conditions such as schizophrenia and Parkinson's disease. 
